Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Indiplon-MR: Phase II results; Phase III

In a double-blind U.S. Phase II study in 79 patients (ages 65-75) with chronic

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE